Amsacrine suppresses matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia cells

Journal of Cellular Physiology

Volumn 229, Issue 5, 2014, Pages 588-598

  Liu, Wen Hsin ^a   Chen, Ying Jung ^a   Chien, Jen Hung ^b   Chang, Long Sen ^a,c  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; AMSACRINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLOHEXIMIDE; DACTINOMYCIN; GELATINASE A; GELATINASE B; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CELL INVASION; CELL STRAIN HL 60; CELL STRAIN K 562; CELL STRAIN KU812; CELL STRAIN MEG 01; CELL STRAIN U937; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA STABILITY; UPREGULATION;

AMSACRINE; DOWN-REGULATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; MAP KINASE KINASE 4; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MOLECULAR STRUCTURE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN PHOSPHATASE 2; RNA, MESSENGER; U937 CELLS; UP-REGULATION;

EID: 84892634974     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24481     Document Type: Article

References (44)

1. Akool el-S, Kleinert H, Hamada FM, Abdelwahab MH, Förstermann U, Pfeilschifter J, Eberhardt W. 2003. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol 23:4901-4916.
2. Baran Y, Ural AU, Gunduz U. 2007. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 12:497-503.
3. Bruchova H, Borovanova T, Klamova H, Brdicka R. 2002. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea. Leuk Lymphoma 43:1289-1295.
4. Chen YW, Chen YL, Tseng CH, Liang CC, Yang CN, Yao YC, Lu PJ, Tzeng CC. 2011. Discovery of 4-anilinofuro[2, 3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers. J Med Chem 54:4446-4461.
5. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
6. Ehsanian R, Van Waes C, Feller SM. 2011. Beyond DNA binding-A review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun Signal 15:9-13.
7. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, Gurova KV. 2009. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-κB and p53 pathways. Oncogene 28:1151-1161.
8. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV. 2005. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 102:17448-17453.
9. Huang YT, Huang DM, Guh JH, Chen IL, Tzeng CC, Teng CM. 2005. CIL-102 interacts with microtubule polymerization and causes mitotic arrest following apoptosis in the human prostate cancer PC-3 cell line. J Biol Chem 280:2771-2779.
10. Iyer V, Pumiglia K, DiPersio CM. 2005. α3β1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes: A novel mechanism of integrin-mediated MMP gene expression. J Cell Sci 118:1185-1195.
11. Jangir DK, Dey SK, Kundu S, Mehrotra R. 2012. Assessment of amsacrine binding with DNA using UV-visible, circular dichroism and Raman spectroscopic techniques. J Photochem Photobiol B 114:38-43.
12. Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA. 2010. Inhibition of NF-κB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem 285:19162-19172.
13. Kaddu S, Zenahlik P, Beham-Schmid C, Kerl H, Cerroni L. 1999. Specific cutaneous infiltrates in patients with myelogenous leukemia: A clinicopathologic study of 26 patients with assessment of diagnostic criteria. J Am Acad Dermatol 40:966-978.
14. Kalia S, Dutz JP. 2007. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 20:160-174.
15. Kaneta Y, Kagami Y, Tsunoda T, Ohno R, Nakamura Y, Katagiri T. 2003. Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. Int J Oncol 23:681-691.
16. Ketron AC, Denny WA, Graves DE, Osheroff N. 2012. Amsacrine as a topoisomerase II poison: Importance of drug-DNA interactions. Biochemistry 51:1730-1739.
17. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ESJM. 2004. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Critical Rev Oncol Hematol 50:87-100.
18. Krishna M, Narang H. 2008. The complexity of mitogen activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 65:3525-3544.
19. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR. 1997. Novel homologues of CSBP/p38 MAP kinase activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 235:533-538.
20. Kuo L, Chang HC, Leu TH, Maa MC, Hung WC. 2006. Src oncogene activates MMP-2 expression via the ERK/Sp1 pathway. J Cell Physiol 207:729-734.
21. Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF. 2002. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: Potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients ith acute myelogenous leukaemia. Br J Haematol 117:835-841.
22. 2+/ROS-mediated suppression of ERK/c-fos pathway and activation of p38 MAPK/c-Jun pathway. J Cell Physiol 224:775-785.
23. Liu J, Xiong W, Baca-Regen L, Nagase H, Baxter BT. 2003. Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg 38:1376-1383.
24. Liu WH, Chen YL, Chang LS. 2012. CIL-102 induces matrix metalloproteinase-2 (MMP-2)/MMP-9 down-regulation via simultaneous suppression of genetic transcription and mRNA stability. Int J Biochem Cell Biol 44:2212-2222.
25. Liu WH, Chou WM, Chang LS. 2013a. p38 MAPK/PP2Acα/TTP pathway on the connection of TNF-α and caspases activation on hydroquinone-induced apoptosis. Carcinogenesis 34:818-827.
26. Liu WH, Chen YJ, Cheng TL, Lin SR, Chang LS. 2013b. Cross talk between p38MAPK and ERK is mediated through MAPK-mediated protein phosphatase 2A catalytic subunit a and MAPK phosphatase-1 expression in human leukemia U937 cells. Cell Signal 25:1845-1851.
27. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. 2007. Topoisomerase IIβ mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67:8839-8846.
28. Murthy S, Ryan AJ, Carter AB. 2012. SP-1 regulation of MMP-9 expression requires Ser586 in the PEST domain. Biochem J 445:229-236.
29. Paupert J, Mansat-De Mas V, Demur C, Salles B, Muller C. 2008. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle 7:1047-1053.
30. Preet R, Mohapatra P, Mohanty S, Sahu SK, Choudhuri T, Wyatt MD, Kundu CN. 2012. Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. Int J Cancer 130:1660-1670.
31. Reunanen N, Li SP, Ahonen M, Foschi M, Han J, Kähäri VM. 2002. Activation of p38α MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. J Biol Chem 277:32360-32368.
32. Sawicki G, Matsuzaki A, Janowska-Wieczorek A. 1998. Expression of the active form of MMP-2 on the surface of leukemic cells accounts for their in vitro invasion, J Cancer Res Clin Oncol 124:245-252.
33. Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, Pae HO. 2011. Mitogen-activated protein kinases and reactive oxygen species: How can ROS activate MAPK pathways? J Signal Transduct 2011:792639.
34. Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, Manca V, Fabbi P, Ballestrero A, Brunelli C, Barsotti A. 2006. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 69:736-745.
35. Stefanidakis M, Koivunen E. 2006. Cell-surface association between matrix metalloproteinases and integrins: Role of the complexes in leukocyte migration and cancer progression. Blood 108:1441-1450.
36. Stuhlmeier KM. 2003. Mepacrine inhibits matrix metalloproteinases-1 (MMP-1) and MMP-9 activation in human fibroblast-like synoviocytes. J Rheumatol 30:2330-2337.
37. Stuhlmeier KM, Pollaschek C. 2006. Quinacrine but not chloroquine inhibits PMA induced upregulation of matrix metalloproteinases in leukocytes: Quinacrine acts at the transcriptional level through a PLA2-independent mechanism. J Rheumatol 33:472-480.
38. Suminoe A, Matsuzaki A, Hattori H, Koga Y, Ishii E, Hara T. 2007. Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement. Leuk Res 31:1437-1440.
39. Taheri F, Bazan HE. 2007. Platelet-activating factor overturns the transcriptional repressor disposition of Sp1 in the expression of MMP-9 in human corneal epithelial cells. Invest Ophthalmol Vis Sci 48:1931-1941.
40. Valdes AF. 2011. Acridine and acridinones: Old and new structures with antimalarial activity. Open Med Chem J 5:11-20.
41. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. 2002. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 37:375-536.
42. Wang W, Ho WC, Dicker DT, MacKinnon C, Winkler JD, Marmorstein R, El-Deiry WS. 2005. Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther 4:893-898.
43. Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou HF, Guo L, Liu W, Wang SJ, Yu XG. 2012. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol 40:1714-1724.
44. Zwelling LA, Mitchell MJ, Satitpunwaycha P, Mayes J, Altschuler E, Hinds M, Baguley BC. 1992. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: Use of computer simulations in new drug development. Cancer Res 52:209-217.